Ask AI
ProCE Banner Events

Share

Treatment of HER2-Low, HR-Positive, and TNBC: A Focus on HER2-Targeted and TROP-2–Targeted Therapy

Register now for this 1.5-hour interactive satellite symposium held in conjunction with the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago, Illinois to hear about how to optimize and personalize the care of patients with HER2-low, HR-positive and triple-negative breast cancer, including recent data and evolving treatment strategies with the use of HER2-targeted and TROP-2-targeted therapies. After the symposium, view the on-demand webcast and download the associated slideset for use in your clinic.

For more information on ASCO’s Health and Safety policy for this event, please visit ASCO’s website.

Not an official event of the 2023 ASCO Annual Meeting. Not sponsored, endorsed, or accredited by ASCO®, CancerLinQ®, or Conquer Cancer®, the ASCO Foundation.

Physicians: maximum of 1.50 AMA PRA Category 1 Credits™

This event has expired. No longer available for credits.

Who Should Attend

This program is intended for medical oncologists, pathologists, and other healthcare professionals caring for patients with breast cancer.

Time and location

Sunday, June 04, 2023

7:00 PM - 8:30 PM Central Time (CT)

In-personVirtual

Hilton Chicago
720 South Michigan Avenue
Chicago, Illinois 60604

Salon A 3-4

Agenda

Registration & Dinner: 6:30-7:00 PM CT

Symposium: 7:00-8:30 PM CT

  • Welcome and Introduction
  • Establishing HER2-Directed Therapies in the Management of HER2-low Breast Cancer
  • Incorporating TROP-2–Targeted Agents into the Breast Cancer Treatment Landscape
  • Practical Adverse Event Prevention, Mitigation and Management Strategies for Optimal Treatment Outcomes
  • Spotlight of Key Abstracts at ASCO 2023
  • Case-Based Panel Discussions
  • Final Thoughts and Audience Question and Answer Session

Location

Venue Name

Hilton Chicago

Address

Hilton Chicago
720 South Michigan Avenue
Chicago, Illinois 60604

Room Name

Salon A 3-4

CME/CE Info

Program Overview
This program will provide expert faculty perspectives on the optimal integration of HER2-directed and TROP-2-targeted therapies into the management of advanced HER2-Low, HR-Positive, and triple-negative breast cancer, and contextualize the role, if any, of HER2 and/or TROP-2 expression as prognostic biomarkers for risk stratification and personalization of patient care using clinical case studies to illustrate how to select and sequence therapy to maximize efficacy and safety. 

Goal Statement
This program aims to improve learners’ knowledge, confidence, and competence in integrating recent approvals, emerging clinical data, and treatment-related adverse event management into clinical practice for the treatment of HER2-low, HR-positive, and triple-negative breast cancer.

Target Audience
This program is intended for medical oncologists, pathologists, and other healthcare professionals caring for patients with breast cancer.

Learning Objectives
Upon completion of this activity, participants should be able to:

  • Plan therapeutic strategies for patients with HER2-low metastatic breast cancer based on the available clinical data and expert recommendations
  • Implement new expert and guideline-recommended testing and assessment of HER2 expression to expand HER2-targeted treatment options to patients who previously would be classified as HER2 negative
  • Develop a treatment plan with agents targeting TROP-2 in patients with TNBC or endocrine-resistant HR-positive/HER2-negative metastatic breast cancer
  • Distinguish current indications, efficacy, and toxicity profiles among available and investigational agents targeting TROP-2 in metastatic breast cancer
  • Construct a supportive care plan for patients experiencing treatment-related symptoms while receiving a HER2- or TROP-2–targeted therapy

Accreditation

Joint Accreditation Statement

In support of improving patient care, Clinical Care Options, LLC (CCO) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC) to provide continuing education for the healthcare team.

Physician Continuing Medical Education

Designation of Credit

CCO designates this live activity for a maximum of 1.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Disclosure of Conflicts of Interest 
Clinical Care Options, LLC (CCO) requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose all financial conflicts of interest (COI) they may have with ineligible companies. All relevant COI are thoroughly vetted and mitigated according to CCO policy. CCO is committed to providing its learners with high-quality CME/CE activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of an ineligible company.

Acknowledgement

Provided by Clinical Care Options, LLC.

Supported by educational grants from AstraZeneca, Daiichi Sankyo, Inc., and Gilead Sciences Inc.

Contact Information

Contact Clinical Care Options

For customer support please click here.

Mailing Address:

 

Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA 20191

Additional Information

There are no fees required to participate in this activity.

Americans With Disabilities Act 
Event staff will be glad to assist you with any special needs (eg, physical, dietary). Please contact customer support prior to the live event.